Performance evaluation of Bruker UMIC® microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkolderia species-Reference-Cited by-同舟云学术

Performance evaluation of Bruker UMIC® microdilution panel and disc diffusion to determine cefiderocol susceptibility in Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkolderia species

Published:2024-01-19 Issue:3 Volume:43 Page:559-566
ISSN:0934-9723
Container-title:European Journal of Clinical Microbiology & Infectious Diseases
language:en
Short-container-title:Eur J Clin Microbiol Infect Dis

Author:

Bianco Gabriele^ORCID,Boattini Matteo,Comini Sara,Gaibani Paolo,Cavallo Rossana,Costa Cristina

Funder

International Society for Infectious Diseases

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10096-024-04745-7.pdf

Reference25 articles.

1. Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis EI (2023) Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis. Clin Microbiol Infect S1198–743X(23)00413-5. https://doi.org/10.1016/j.cmi.2023.08.029

2. Sato T, Yamawaki K (2019) Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis 69:S538–S543. https://doi.org/10.1093/cid/ciz826

3. Simner PJ, Patel R (2020) Cefiderocol antimicrobial susceptibility testing considerations: the Achilles’ Heel of the Trojan Horse? J Clin Microbiol 59:e00951-e1020. https://doi.org/10.1128/JCM.00951-20

4. Bianco G, Boattini M, Comini S, Banche G, Cavallo R, Costa C (2023) Disc diffusion and ComASP® cefiderocol microdilution panel to overcome the challenge of cefiderocol susceptibility testing in clinical laboratory routine. Antibiotics (Basel) 12:604. https://doi.org/10.3390/antibiotics12030604

5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Thirtieth Informational Supplement. Wayne, PA: M100-S30. Clinical and Laboratory Standards Institute; 2020.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cefiderocol – An effective antimicrobial for MDR infections but a challenge for routine antimicrobial susceptibility testing;Advances in Medical Sciences;2024-09

2. Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint;Journal of Global Antimicrobial Resistance;2024-09

3. Commercially available tests for determining cefiderocol susceptibility display variable performance in the Achromobacter genus;Annals of Clinical Microbiology and Antimicrobials;2024-08-22

4. Comparison of Different Methods for Assaying the In Vitro Activity of Cefiderocol against Carbapenem-Resistant Pseudomonas aeruginosa Strains: Influence of Bacterial Inoculum;Antibiotics;2024-07-18

5. Clinical and microbiological features of positive blood culture episodes caused by non-fermenting gram-negative bacilli other than Pseudomonas and Acinetobacter species (2020–2023);Infection;2024-07-11